TEDISAMIL SESQUIFUMARATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	2C19H32N2.3C4H4O4
Molecular Weight	925.158
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	3
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.C(C1CC1)N2CC3CN(CC4CC4)CC(C2)C35CCCC5.C(C6CC6)N7CC8CN(CC9CC9)CC(C7)C8%10CCCC%10

InChI

InChIKey=AZPYPAVFNGFTGB-VQYXCCSOSA-N

InChI=1S/2C19H32N2.3C4H4O4/c2*1-2-8-19(7-1)17-11-20(9-15-3-4-15)12-18(19)14-21(13-17)10-16-5-6-16;3*5-3(6)1-2-4(7)8/h2*15-18H,1-14H2;3*1-2H,(H,5,6)(H,7,8)/b;;3*2-1+

HIDE SMILES / InChI

Molecular Formula	C4H4O4
Molecular Weight	116.0722
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Molecular Formula	C19H32N2
Molecular Weight	288.4708
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.fdanews.com/articles/102230-advisory-committee-recommends-no-approval-for-pulzium?v=preview | https://clinicaltrials.gov/ct2/show/NCT00126061 | http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con031129.pdf | https://www.ncbi.nlm.nih.gov/pubmed/14996649 | https://www.ncbi.nlm.nih.gov/pubmed/11527020

Tedisamil is an antiarrhythmic with additional anti-ischaemic properties, which acts via potassium channel blockade. This drug can be categorised as a class III antiarrhythmic agent due to its effects of action potential and QT interval prolongation in these patients. Although tedisamil has been shown to be an effective anti-ischaemic agent, with Phase III trials for angina pectoris now completed, the company are now pursuing the use of tedisamil for the treatment of atrial fibrillation, for which tedisamil is still in Phase II/III clinical trials. The FDA’s Cardiovascular and Renal Drugs Advisory Committee voted not to recommend approval for Solvay Pharmaceuticals’ investigational anti-arrhythmic drug Pulzium (Tedisamil) and asked the company to give the FDA more information.

Originator

Approval Year

PubMed

Title	Date	PubMed
Effects of tedisamil on cardiovascular tissues isolated from normo- and hypertensive rats.	2001 Jul	11584333
Transgenic mice overexpressing human KvLQT1 dominant-negative isoform. Part II: Pharmacological profile.	2001 May	11334836
Conversion of atrial fibrillation by the experimental antiarrhythmic drug tedisamil in two canine models.	2001 Oct	11699522
New antiarrhythmic drugs for the treatment of atrial fibrillation.	2002 Feb	11916001
Tedisamil blocks BK-type Ca(2+)-dependent K(+) channels and modulates action potentials in rat hippocampal neurons.	2002 Feb 15	11825675
Bertosamil blocks HERG potassium channels in their open and inactivated states.	2002 Sep	12208779
Tedisamil and lidocaine enhance each other's antiarrhythmic activity against ischaemia-induced arrhythmias in rats.	2003 Aug	12922925
Tedisamil in coronary disease: additional benefits in the therapy of atrial fibrillation?	2003 Jun	12746750
Antiarrhythmic drug therapy of atrial fibrillation: focus on new agents.	2003 Jun	12746749
Atrial fibrillation: emerging possibilities for drug treatment: an overview of current opportunities and recent developments.	2003 Jun	12746746
Role of atrial fibrillation threshold evaluation on guiding treatment.	2003 Oct 1	16943922
Trials of new antiarrhythmic drugs for maintenance of sinus rhythm in patients with atrial fibrillation.	2004	14739742
Trial finds new anti-arrhythmic, tedisamil, is superior to placebo for converting recent onset atrial fibrillation or atrial flutter.	2004 Dec	16379966
Tedisamil: a new novel antiarrhythmic.	2004 Feb	14996649
Role of pharmacotherapy in Brugada syndrome.	2004 Jan 1	16943885
Electrical storms in Brugada syndrome: review of pharmacologic and ablative therapeutic options.	2005 Jan 1	16943940
Update on atrial fibrillation: part II.	2008 Mar	18383050
New horizons in antiarrhythmic therapy: will novel agents overcome current deficits?	2008 Sep 22	18790110
The transmembrane beta-subunits KCNE1, KCNE2, and DPP6 modify pharmacological effects of the antiarrhythmic agent tedisamil on the transient outward current Ito.	2009 Jun	19153714
Clinically important interaction between tedisamil and verapamil.	2009 May	19299533

Sample Use Guides

In Vivo Use Guide

The recommended dose is 0.32 mg/kg

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:04:28 GMT 2023` Edited by `admin` on `Fri Dec 15 16:04:28 GMT 2023`
Record UNII	Y4HRG433UU
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TEDISAMIL SESQUIFUMARATE

Official Name

English

KC-8857 SESQUIFUMARATE

Code

English

TEDISAMIL SESQUIFUMARATE [USAN]

Common Name

English

Tedisamil sesquifumarate [WHO-DD]

Common Name

English

PULZIUM

Brand Name

English

SPIRO(CYCLOPENTANE-1,9'-(3,7)DIAZABICYCLO(3.3.1)NONANE), 3',7'-BIS(CYCLOPROPYLMETHYL)-, (2E)-2-BUTENEDIOATE (2:3)

Common Name

English

TEDISAMIL SESQUIFUMARATE [MI]

Common Name

English

BIS(3',7'-BIS(CYCLOPROPYLMETHYL)SPIRO(CYCLOPENTANE-1,9'-(3,7)DIAZABICYCLO(3.3.1)NONANE))DIHYDROGEN TRIS((2E-BUT-2-ENEDIOATE)

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C93038